Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in Europe.

The relative importance of human diseases is conventionally assessed by cause-specific mortality, morbidity, and economic impact. Current estimates for infections caused by antibiotic-resistant bacteria are not sufficiently supported by quantitative empirical data. This study determined the excess n...

Full description

Bibliographic Details
Main Authors: Marlieke E A de Kraker, Peter G Davey, Hajo Grundmann, BURDEN study group
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-10-01
Series:PLoS Medicine
Online Access:http://europepmc.org/articles/PMC3191157?pdf=render
id doaj-0e0eb397e2ba4abf87a0276903c53223
record_format Article
spelling doaj-0e0eb397e2ba4abf87a0276903c532232020-11-24T21:12:25ZengPublic Library of Science (PLoS)PLoS Medicine1549-12771549-16762011-10-01810e100110410.1371/journal.pmed.1001104Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in Europe.Marlieke E A de KrakerPeter G DaveyHajo GrundmannBURDEN study groupThe relative importance of human diseases is conventionally assessed by cause-specific mortality, morbidity, and economic impact. Current estimates for infections caused by antibiotic-resistant bacteria are not sufficiently supported by quantitative empirical data. This study determined the excess number of deaths, bed-days, and hospital costs associated with blood stream infections (BSIs) caused by methicillin-resistant Staphylococcus aureus (MRSA) and third-generation cephalosporin-resistant Escherichia coli (G3CREC) in 31 countries that participated in the European Antimicrobial Resistance Surveillance System (EARSS).The number of BSIs caused by MRSA and G3CREC was extrapolated from EARSS prevalence data and national health care statistics. Prospective cohort studies, carried out in hospitals participating in EARSS in 2007, provided the parameters for estimating the excess 30-d mortality and hospital stay associated with BSIs caused by either MRSA or G3CREC. Hospital expenditure was derived from a publicly available cost model. Trends established by EARSS were used to determine the trajectories for MRSA and G3CREC prevalence until 2015. In 2007, 27,711 episodes of MRSA BSIs were associated with 5,503 excess deaths and 255,683 excess hospital days in the participating countries, whereas 15,183 episodes of G3CREC BSIs were associated with 2,712 excess deaths and 120,065 extra hospital days. The total costs attributable to excess hospital stays for MRSA and G3CREC BSIs were 44.0 and 18.1 million Euros (63.1 and 29.7 million international dollars), respectively. Based on prevailing trends, the number of BSIs caused by G3CREC is likely to rapidly increase, outnumbering the number of MRSA BSIs in the near future.Excess mortality associated with BSIs caused by MRSA and G3CREC is significant, and the prolongation of hospital stay imposes a considerable burden on health care systems. A foreseeable shift in the burden of antibiotic resistance from Gram-positive to Gram-negative infections will exacerbate this situation and is reason for concern.http://europepmc.org/articles/PMC3191157?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Marlieke E A de Kraker
Peter G Davey
Hajo Grundmann
BURDEN study group
spellingShingle Marlieke E A de Kraker
Peter G Davey
Hajo Grundmann
BURDEN study group
Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in Europe.
PLoS Medicine
author_facet Marlieke E A de Kraker
Peter G Davey
Hajo Grundmann
BURDEN study group
author_sort Marlieke E A de Kraker
title Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in Europe.
title_short Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in Europe.
title_full Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in Europe.
title_fullStr Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in Europe.
title_full_unstemmed Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in Europe.
title_sort mortality and hospital stay associated with resistant staphylococcus aureus and escherichia coli bacteremia: estimating the burden of antibiotic resistance in europe.
publisher Public Library of Science (PLoS)
series PLoS Medicine
issn 1549-1277
1549-1676
publishDate 2011-10-01
description The relative importance of human diseases is conventionally assessed by cause-specific mortality, morbidity, and economic impact. Current estimates for infections caused by antibiotic-resistant bacteria are not sufficiently supported by quantitative empirical data. This study determined the excess number of deaths, bed-days, and hospital costs associated with blood stream infections (BSIs) caused by methicillin-resistant Staphylococcus aureus (MRSA) and third-generation cephalosporin-resistant Escherichia coli (G3CREC) in 31 countries that participated in the European Antimicrobial Resistance Surveillance System (EARSS).The number of BSIs caused by MRSA and G3CREC was extrapolated from EARSS prevalence data and national health care statistics. Prospective cohort studies, carried out in hospitals participating in EARSS in 2007, provided the parameters for estimating the excess 30-d mortality and hospital stay associated with BSIs caused by either MRSA or G3CREC. Hospital expenditure was derived from a publicly available cost model. Trends established by EARSS were used to determine the trajectories for MRSA and G3CREC prevalence until 2015. In 2007, 27,711 episodes of MRSA BSIs were associated with 5,503 excess deaths and 255,683 excess hospital days in the participating countries, whereas 15,183 episodes of G3CREC BSIs were associated with 2,712 excess deaths and 120,065 extra hospital days. The total costs attributable to excess hospital stays for MRSA and G3CREC BSIs were 44.0 and 18.1 million Euros (63.1 and 29.7 million international dollars), respectively. Based on prevailing trends, the number of BSIs caused by G3CREC is likely to rapidly increase, outnumbering the number of MRSA BSIs in the near future.Excess mortality associated with BSIs caused by MRSA and G3CREC is significant, and the prolongation of hospital stay imposes a considerable burden on health care systems. A foreseeable shift in the burden of antibiotic resistance from Gram-positive to Gram-negative infections will exacerbate this situation and is reason for concern.
url http://europepmc.org/articles/PMC3191157?pdf=render
work_keys_str_mv AT marliekeeadekraker mortalityandhospitalstayassociatedwithresistantstaphylococcusaureusandescherichiacolibacteremiaestimatingtheburdenofantibioticresistanceineurope
AT petergdavey mortalityandhospitalstayassociatedwithresistantstaphylococcusaureusandescherichiacolibacteremiaestimatingtheburdenofantibioticresistanceineurope
AT hajogrundmann mortalityandhospitalstayassociatedwithresistantstaphylococcusaureusandescherichiacolibacteremiaestimatingtheburdenofantibioticresistanceineurope
AT burdenstudygroup mortalityandhospitalstayassociatedwithresistantstaphylococcusaureusandescherichiacolibacteremiaestimatingtheburdenofantibioticresistanceineurope
_version_ 1716751020038553600